Editas medicine stock price.

Editas Medicine Inc stock price live 10.42, this page displays NASDAQ EDIT stock exchange data. View the EDIT premarket stock price ahead of the market session or assess the after hours quote.Nov 21, 2023 · Editas Medicine stock forecasts are adjusted once a day based on the closing price of the previous trading day. The minimum target price for Editas Medicine analysts is $ 13.53 . Today 200 Day Moving Average is the resistance level ( 8.45 $). Editas Medicine, Inc. (EDIT) is a clinical-stage genome editing company that develops treatments for cancer and other diseases. The stock price, news, quote and history of EDIT are shown on Yahoo Finance. See the latest performance outlook, earnings date, dividend yield, fair value and more. Editas Medicine stock forecasts are adjusted once a day based on the closing price of the previous trading day. The minimum target price for Editas Medicine analysts is $ 13.53 . Today 200 Day Moving Average is the resistance level ( 8.45 $).

Our indicative theme on Gene Editing Stocks - which includes names such as CRISPR Therapeutics, Editas Medicine, and others - has returned about 230% over the past 2 years, compared to the broader ...Shares of Editas Medicine ( EDIT -0.26%) were down as much as 21% at one point on Thursday. The stock closed at $12.25 on Wednesday and opened at only $9.90 on Thursday, falling to as low as $9.61 ...Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus. Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.

The stock option provides for the purchase of up to 123,350 shares of Editas Medicine common stock at a price of $8.00 per share, the closing price per share of Editas Medicine common stock as reported by Nasdaq on the date of grant, and vests over four years, with 25 percent of the shares vesting on the first anniversary of Ms. Deardorf’s ...Price as of December 1, 2023, 4:00 p.m. ET ... Shares of Editas Medicine (EDIT 2.28%) are sliding today, down by 7.2% as of 11:26 a.m. ET. The decline came after the company announced a big shake ...

Editas Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. Nov. 03. CI. North American Morning Briefing : S&P 500 Futures -2-. Nov. 03. DJ. Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored ... Current Price. $10.58. Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street.Nov 3, 2023 · Editas Medicine (EDIT) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.64. ... The sustainability of the stock's immediate price movement ...

intraday 1w 1m 6m ytd 1y 3y 5y max Mountain-Chart Compare with Compare with up to 5 Stocks On Friday 12/01/2023 the closing price of the Editas …

Editas Medicine ended the third quarter with $478.5 million in cash and equivalents, compared to $657 million as of Q3 2021. It reported a net loss of $55.7 million during the period, worse than ...

Jun 28, 2023 · Current Price. $10.58. Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ... The stock price of Editas Medicine, a biotechnology company focused on developing treatments using gene editing technology, has seen a rise of over 20% over the last twenty-one trading days, and ...Nov 29, 2023 · The average price recommended by analysts for Editas Medicine Inc (EDIT) is $13.93, which is $3.19 above the current market price. The public float for EDIT is 81.05M and currently, short sellers hold a 19.58% of that float. On November 29, 2023, EDIT’s average trading volume was 1.64M shares. EDIT) stock’s latest price update Get the latest Editas Medicine, Inc. (EDIT) stock news and headlines to help you in your trading and investing decisions.View Editas Medicine, Inc EDIT investment & stock information. Get the latest Editas Medicine, Inc EDIT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Editas Medicine, Inc. Common Stock (EDIT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Price as of December 1, 2023, 4:00 p.m. ET ... Shares of Editas Medicine (EDIT 2.28%) are sliding today, down by 7.2% as of 11:26 a.m. ET. The decline came after the company announced a big shake ...

Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.The Editas Medicine stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.Editas Medicine releases earnings for the most recent quarter on November 3. Analysts predict Editas Medicine will release losses per share of $0.575. Go here to track Editas Medicine stock price ...CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses.In the last 3 months, 18 analysts have offered 12-month price targets for Editas Medicine. The company has an average price target of $19.17 with a high of $43.00 and a low of $6.00.

A medicine is any substance that is designed to prevent or treat diseases and a drug is designed to produce a specific reaction inside the body. While there is considerable overlap between the two types of substances, these differences are ...11.34%. Get the latest Editas Medicine Inc (EDIT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...

View the latest Editas Medicine Inc. (EDIT) stock price, news, historical charts, analyst ratings and financial information from WSJ. Sep 30, 2020 · Current Price. $10.65. Price as of November 27, 2023, 4:00 p.m. ET. Both are working on gene-editing therapies, with plenty of potential upside. But which is the better stock right now? You can't ... A cough can be annoying, and it can affect you day and night. There are many cough medicines available over-the-counter but it’s hard to know which one is the best to alleviate your symptoms. This article will help break down the best over-...Editas Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. Nov. 03. CI. North American Morning Briefing : S&P 500 Futures -2-. Nov. 03. DJ. Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored ... Nov 17, 2023 · Get Editas Medicine Inc (EDIT.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments On June 15, Editas Medicine ( EDIT 2.23%) saw its shares collapse by 15% after announcing it would be issuing new stock to raise approximately $125 million. The biotech will almost certainly use ...EDIT - Editas Medicine Inc Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ)Editas Medicine has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock on the same terms and conditions. All of the shares in the offering ...

It's been a tough year for Editas Medicine (EDIT-0.26%) so far. As of the market close on Monday, the stock was down 42%. But shares of Editas were rebounding by 8.2% as of 11:25 a.m. EST on ...

Why Editas Medicine's Shares Jumped This Week. (Motley Fool) Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, …

Editas Medicine Inc’s Stock Price as of Market Close. As of May 16, 2023, 4:00 PM CST, Editas Medicine Inc’s stock price was $9.55. Editas Medicine Inc is down 4.6% from its previous closing price of $10.01. During the last market session, Editas Medicine Inc’s stock traded between $9.58 and $10.51. Currently, there are 68.92 …Real-time Price Updates for Editas Medicine (EDIT-Q), along with buy or sell indicators, analysis, charts, historical performance, news and moreOn Wednesday, Editas Medicine Inc [NASDAQ: EDIT] rose 3.76% to $8.84. The stock’s lowest price that day was $8.50, but it reached a high of $9.15 in the same session. During the last five days, there has been a surge of approximately 5.24%. Over the course of the year, Editas Medicine Inc shares have dropped approximately -0.34%.The current Editas Medicine [ EDIT] share price is $9.78. The Score for EDIT is 55, which is 10% above its historic median score of 50, and infers lower risk than normal. EDIT is currently trading in the 50-60% percentile range relative to its historical Stock Score levels.Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.In the last 3 months, 18 analysts have offered 12-month price targets for Editas Medicine. The company has an average price target of $19.17 with a high of $43.00 and a low of $6.00.The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m. ET to provide and discuss a corporate update and financial results for the second quarter of 2023. To access the call, please dial 1-877-407-0989 (domestic) or 1-201-389-0921 (international) and ask for the Editas Medicine earnings call.Editas Medicine (EDIT) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to loss of $0.57 per share a year ago. These figures ...

Sep 30, 2020 · Current Price. $10.65. Price as of November 27, 2023, 4:00 p.m. ET. Both are working on gene-editing therapies, with plenty of potential upside. But which is the better stock right now? You can't ... With all that said, here are the most exciting genomic stocks that you won’t want to miss out on. NTLA Intellia Therapeutics $37.75 BEAM Beam Therapeutics $30.71 EDIT Editas Medicine $8.16.Check out our EDIT stock analysis, current EDIT quote, charts, and historical prices for Editas Medicine stockNov 17, 2023 · Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 46.41% so far this month. During the month of November, Editas Medicine Inc’s stock price has reached a high of $9.83 and a low of $6.66. Over the last year, Editas Medicine Inc has hit prices as high as $11.93 and as low as $6.08. Year to date, Editas ... Instagram:https://instagram. tesla option chainstock screener for day tradingprocept biorobotics stockstocks under 40 dollars Editas Medicine (EDIT) Stock Price Performance. Editas Medicine (EDIT) Stock Key Data. ... Consensus Price Target is the stock price analysts expect to see within a period of 0-18 months.Editas Medicine. Market Cap. $860M. Today's Change. (-0.75%) -$0.08. Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. You’re reading a free article with opinions that may ... nyse borrcummins share price Jun 15, 2023 · CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses. best strategy for day trading Check out our EDIT stock analysis, current EDIT quote, charts, and historical prices for Editas Medicine stockEstablishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Real time Editas Medicine (EDIT) stock price quote, stock graph, news & analysis.